The Economic Burden of Different Multiple Sclerosis Courses: Analysis from Italian Administrative and Clinical Databases

Paolo Angelo Cortesi, Paolo Cozzolino, Ruggero Capra, Giancarlo Cesana, Lorenzo Giovanni Mantovani

DOI: https://doi.org/10.7175/fe.v21i1.1476

Abstract

INTRODUCTION: Poor specific economic information are available for the different Multiple Sclerosis (MS) courses: relapsing remitting (RRMS), secondary progressive (SPMS) and primary progressive (PPMS). This study aims to fill this gap.

METHODS: A cost of illness study was conducted. Clinical information of patients treated in a major MS Center located in Lombardy, in the period 2004-2010, were linked with administrative data of Lombardy Healthcare System. We assessed the mean cost per patient-year and its association with different MS characteristics.

RESULTS: The study identified 869 patients (83.9% RRMS, 8.5% SPMS, 7.2% PPMS). RRMS reported the highest cost per patient-year with a mean of € 5,623 in Expanded Disability Status Scale (EDSS) 0-3, € 8,675 in EDSS 3.5-6.5, and € 7,451 in EDSS 7-9. The PPMS patients reported the lower annual mean cost per patient in all EDSS categories. The mul-tivariate analysis reported a significant association between cost per patient-year and EDSS categories, relapse and use of Disease Modifying Therapies but not to MS courses, age and sex.

CONCLUSION: This study provides a complete picture of MS courses direct costs at the different disability levels. The results can help to better understand the burden of each MS courses and the cost-effectiveness of different interventions.

Keywords

Multiple sclerosis; Burden of disease; Direct costs; Italy

Full Text

HTML

References

  • GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017; 16: 877-97; https://doi.org/10.1016/S1474-4422(17)30299-5
  • Brownlee WJ, Hardy TA, Fazekas F, et al. Diagnosis of multiple sclerosis: progress and challenges. Lancet 2017; 389: 1336-46; https://doi.org/10.1016/S0140-6736(16)30959-X
  • Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med 2018; 378: 169-80; https://doi.org/10.1056/NEJMra1401483
  • Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302; https://doi.org/10.1002/ana.22366
  • Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278-86; https://doi.org/10.1212/WNL.0000000000000560
  • Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ 2013; 16: 639-47; https://doi.org/10.3111/13696998.2013.778268
  • Kobelt G, Thompson A, Berg J, et al.; MSCOI Study Group; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 2017; 23: 1123-36; https://doi.org/10.1177/1352458517694432
  • Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006; 77: 918-26; https://doi.org/10.1136/jnnp.2006.090365
  • Ernstsson, O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis - a systematic review. PLoS ONE 2016; 11: e0159129; https://doi.org/10.1371/journal.pone.0159129
  • Gyllensten H, Kavaliunas A, Alexanderson K, et al. Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden. Mult Scler J Exp Transl Clin 2018; 4: 2055217318783352; https://doi.org/10.1177/2055217318783352
  • Gyllensten H, Wiberg M, Alexanderson K, et al. Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age. Eur J Health Econ 2018; 19: 435-46; https://doi.org/10.1007/s10198-017-0894-6
  • Svendsen B, Myhr KM, Nyland H, et al. The cost of multiple sclerosis in Norway. Eur J Health Econ 2012; 13: 81-91; https://doi.org/10.1007/s10198-010-0286-7
  • Jennum P, Wanscher B, Frederiksen J, et al. The socioeconomic consequences of multiple sclerosis: a controlled national study. Eur Neuropsychopharmacol 2012; 22: 36-43; https://doi.org/10.1016/j.euroneuro.2011.05.001
  • Montalban X, Hauser SL, Kappos L, et al.; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376: 209-20; https://doi.org/10.1056/NEJMoa1606468
  • Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ 2018; 19: 123-52; https://doi.org/10.1007/s10198-017-0871-0
  • Cortesi PA, Assietti R, Cuzzocrea F, et al. Epidemiologic and Economic Burden Attributable to First Spinal Fusion Surgery: Analysis From an Italian Administrative Database. Spine (Phila Pa 1976) 2017; 42: 1398-404; https://doi.org/10.1097/BRS.0000000000002118
  • Fornari C, Madotto F, Demaria M, et al. Record-linkage procedures in epidemiology: an Italian multicentre study. Epidemiol Prev 2008; 32 (3 Suppl): 79-88
  • Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One 2014; 9: e101228; https://doi.org/10.1371/journal.pone.0101228
  • Iannazzo S, Iliza AC, Perrault L. Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies. Pharmacoeconomics 2018; 36: 189-204; https://doi.org/10.1007/s40273-017-0577-2
  • Battaglia M, Kobelt G, Ponzio M, et al.; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy. Mult Scler 2017; 23(2_suppl): 104-16; https://doi.org/10.1177/1352458517708176
  • Scalone L, Fagiuoli S, Ciampichini R, et al. The societal burden of chronic liver diseases: results from the COME study. BMJ Open Gastroenterol 2015; 2: e000025; https://doi.org/10.1136/bmjgast-2014-000025
  • Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler 2012; 18(2 Suppl): 29-34; https://doi.org/10.1177/1352458512441566c
  • Tyas D, Kerrigan J, Russell N, et al. The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value Health 2007; 10: 386-9; https://doi.org/10.1111/j.1524-4733.2007.00192.x
  • Italian Association of Multiple Sclerosis (AISM). Barometro della sclerosi multipla 2018. AISM, 2018. Available at: https://www.aism.it/il_barometro_della_sm_2018 (last accessed July 2019)
  • Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler 2012; 18(2 Suppl): 7-15; https://doi.org/10.1177/1352458512441566
  • Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007; 10: 54-60; https://doi.org/10.1111/j.1524-4733.2006.00144.x
  • Nazareth TA, Rava AR, Polyakov JL, et al. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey. Mult Scler Relat Disord 2018; 26: 219-34; https://doi.org/10.1016/j.msard.2018.09.002
  • O’Connor P, Wolinsky JS, Confavreux C, et al.; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-303; https://doi.org/10.1056/NEJMoa1014656
  • Kappos L, Radue EW, O’Connor P, et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401; https://doi.org/10.1056/NEJMoa0909494
  • Coles AJ, Twyman CL, Arnold DL, et al.; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380: 1829-39; https://doi.org/10.1016/S0140-6736(12)61768-1
  • Gold R, Kappos L, Arnold DL, et al.; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-107; https://doi.org/10.1056/NEJMoa1114287
  • Capra R, Cordioli C, Rasia S, et al. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. Mult Scler 2017; 23: 1757-61; https://doi.org/10.1177/1352458516687402
  • Furneri G, Santoni L, Marchesi C, et al. Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy. Farmeconomia. Health economics and therapeutic pathways 2016; 17: 67-80; https://doi.org/10.7175/fe.v17i2.1251
  • Guarrera GM, Furian C, Eleopra R, et al. Health Technology Assessment: Fingolimod. QIJPH 2013; 11
  • Dorman E, Kansal AR, Sarda S. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada. J Med Econ 2015; 18: 1085-91; https://doi.org/10.3111/13696998.2015.1076826
  • Furneri G, Marchesi C, Santoni L. Budget impact analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy. Farmeconomia. Health economics and therapeutic pathways 2016; 17: 29-39; https://doi.org/10.7175/fe.v17i1.1237

Statistics

Abstract: 219 views
HTML: 121 views

Refbacks

  • There are currently no refbacks.




© SEEd srl